The complex identity of brain tumors: emerging concerns regarding origin, diversity and plasticity

Elucidation of genetic and epigenetic mechanisms underlying neoplasia is one of the great success stories of modern science, but this success has not been associated with parallel improvements in the treatment of malignant tumors. One possible explanation for this failure is that the most important variables that support growth of malignancies are not yet identified. Another possible explanation, however, is that multiple variables important in neoplastic progression combine to create a level of disease complexity not taken into account by current therapeutic approaches. The study of development and neoplasia in the CNS provides some of the strongest support for the latter view--a view that, if correct, would suggest that a radical rethinking of the biology of malignancy is required if we are to make progress in the treatment of this important medical condition.

[1]  William A Weiss,et al.  Genetic determinants of malignancy in a mouse model for oligodendroglioma. , 2003, Cancer research.

[2]  J. Costello.  DNA methylation in brain development and gliomagenesis. , 2003, Frontiers in bioscience : a journal and virtual library.

[3]  M. Grompe,et al.  Cell fusion is the principal source of bone-marrow-derived hepatocytes , 2003, Nature.

[4]  Jean-Yves Delattre,et al.  OLIG2 as a specific marker of oligodendroglial tumour cells , 2001, The Lancet.

[5]  R A Betensky,et al.  Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. , 2001, Cancer research.

[6]  E. Holland,et al.  Using mice to decipher the molecular genetics of brain tumors. , 2003, Neurosurgery.

[7]  M. Noble,et al.  Identification of an adult-specific glial progenitor cell. , 1989, Development.

[8]  M. Noble,et al.  Getting a GR(i)P on oligodendrocyte development. , 2004, Developmental biology.

[9]  V. Jung,et al.  Frequent mitotic errors in tumor cells of genetically micro-heterogeneous glioblastomas , 2001, Cytogenetic and Genome Research.

[10]  Webster K. Cavenee,et al.  Pathology and genetics of tumours of the nervous system. , 2000 .

[11]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[12]  W. Shapiro,et al.  The subpopulations and isolated cell types of freshly resected high grade human gliomas: Their influence on the tumor's evolutionin vivo and behavior and therapyin vitro , 2004, Cancer and Metastasis Reviews.

[13]  Andreas von Deimling,et al.  Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. , 2002, The American journal of pathology.

[14]  F. Wright,et al.  Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas–Implications for tumor biology and potential clinical utility , 2001, Oncogene.

[15]  David J Anderson,et al.  Identification of a Novel Family of Oligodendrocyte Lineage-Specific Basic Helix–Loop–Helix Transcription Factors , 2000, Neuron.

[16]  G. Fuller,et al.  Genetic Modeling of Glioma Formation in Mice , 2002, Brain pathology.

[17]  W. Shapiro,et al.  Clonal Tumor Cell Heterogeneity1 , 1984 .

[18]  S B Green,et al.  Patient age, histologic features, and length of survival in patients with glioblastoma multiforme , 1987, Cancer.

[19]  Qi-Long Ying,et al.  Changing potency by spontaneous fusion , 2002, Nature.

[20]  D. Rowitch,et al.  Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[21]  J. Cairncross,et al.  Successful chemotherapy for recurrent malignant oligodendroglioma , 1988, Annals of neurology.

[22]  Joanne Chan,et al.  Sonic Hedgehog–Regulated Oligodendrocyte Lineage Genes Encoding bHLH Proteins in the Mammalian Central Nervous System , 2000, Neuron.

[23]  Helen M. Blau,et al.  Stable reprogrammed heterokaryons form spontaneously in Purkinje neurons after bone marrow transplant , 2003, Nature Cell Biology.

[24]  D. Louis,et al.  PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. , 2001, Genes & development.

[25]  M. Nakafuku,et al.  Dynamic expression of basic helix-loop-helix Olig family members: implication of Olig2 in neuron and oligodendrocyte differentiation and identification of a new member, Olig3 , 2000, Mechanisms of Development.

[26]  D. Steindler,et al.  Human cortical glial tumors contain neural stem‐like cells expressing astroglial and neuronal markers in vitro , 2002, Glia.

[27]  Arturo Alvarez-Buylla,et al.  Neurogenesis in Adult Subventricular Zone , 2002, The Journal of Neuroscience.

[28]  M. Noble,et al.  In vitro analysis of the origin and maintenance of O-2Aadult progenitor cells , 1992, The Journal of cell biology.

[29]  S. Williams,et al.  Immortalization and transformation are associated with specific alterations in choline metabolism. , 1996, Cancer research.

[30]  D. Rades,et al.  Treatment options for central neurocytoma , 2002, Neurology.

[31]  M Noble,et al.  Differential expression of drug resistance genes and chemosensitivity in glial cell lineages correlate with differential response of oligodendrogliomas and astrocytomas to chemotherapy. , 2000, Cancer research.

[32]  M. Noble,et al.  Ras‐mediated cell cycle arrest is altered by nuclear oncogenes to induce Schwann cell transformation. , 1988, The EMBO journal.

[33]  M. Raff,et al.  A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium , 1983, Nature.

[34]  E. Scott,et al.  Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion , 2002, Nature.

[35]  D. Figarella-Branger,et al.  Shared oligodendrocyte lineage gene expression in gliomas and oligodendrocyte progenitor cells. , 2003, Journal of neurosurgery.

[36]  L. Larizza,et al.  Acquisition of high metastatic capacity after in vitro fusion of a nonmetastatic tumor line with a bone marrow-derived macrophage , 1984, The Journal of experimental medicine.

[37]  M. Caligiuri,et al.  Aberrant CpG-island methylation has non-random and tumour-type–specific patterns , 2000, Nature Genetics.

[38]  A. Mutirangura,et al.  Genetic heterogeneity and progression in different areas within high-grade diffuse astrocytoma. , 2000, Oncology reports.

[39]  P. Pedersen,et al.  Glucose Metabolism in Cancer , 2003, The Journal of Biological Chemistry.

[40]  Y. Lazebnik,et al.  Cell fusion: a hidden enemy? , 2003, Cancer cell.

[41]  M. Mehler,et al.  Differential modulation of BMP signaling promotes the elaboration of cerebral cortical GABAergic neurons or oligodendrocytes from a common sonic hedgehog-responsive ventral forebrain progenitor species , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[42]  D. Rowitch,et al.  An ‘oligarchy’ rules neural development , 2002, Trends in Neurosciences.

[43]  Z. Kaprielian,et al.  Oligodendrocyte and astrocyte development in rodents: An in situ and immunohistological analysis during embryonic development , 2002, Glia.

[44]  T. Golub,et al.  Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. , 2003, Cancer research.

[45]  D. M. Walker,et al.  Molecular Markers that Identify Human Astrocytomas and Oligodendrogliomas , 2002, Journal of neuropathology and experimental neurology.

[46]  M. Waterfield,et al.  Platelet-derived growth factor promotes division and motility and inhibits premature differentiation of the oligodendrocyte/type-2 astrocyte progenitor ceil , 1988, Nature.

[47]  Seyed E. Hasnain,et al.  Extensive Intra-tumor Heterogeneity in Primary Human Glial Tumors as a Result of Locus Non-specific Genomic Alterations , 2000, Journal of Neuro-Oncology.

[48]  J. Herman,et al.  5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.

[49]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Tao Sun,et al.  Common Developmental Requirement for Olig Function Indicates a Motor Neuron/Oligodendrocyte Connection , 2002, Cell.

[51]  M. Noble,et al.  Oligodendrocyte precursor cells from different brain regions express divergent properties consistent with the differing time courses of myelination in these regions. , 2002, Developmental biology.

[52]  R. DePinho,et al.  Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. , 2002, Cancer cell.

[53]  D. Gass,et al.  The Cortical Ancestry of Oligodendrocytes: Common Principles and Novel Features , 2003, Developmental Neuroscience.

[54]  M. Noble,et al.  A tripotential glial precursor cell is present in the developing spinal cord. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[55]  Webster K. Cavenee,et al.  The WHO Classification of Tumors of the Nervous System , 2002 .

[56]  Richard Reynolds,et al.  The oligodendrocyte precursor cell in health and disease , 2001, Trends in Neurosciences.

[57]  D. Gutmann,et al.  Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model. , 2003, Cancer research.

[58]  Y. Nabeshima,et al.  The Basic Helix-Loop-Helix Factor Olig2 Is Essential for the Development of Motoneuron and Oligodendrocyte Lineages , 2002, Current Biology.

[59]  Andreas von Deimling,et al.  Impact of Genotype and Morphology on the Prognosis of Glioblastoma , 2002, Journal of neuropathology and experimental neurology.

[60]  J. Cairncross,et al.  Successful chemotherapy for newly diagnosed aggressive oligodendroglioma , 1990, Annals of neurology.

[61]  M. Noble,et al.  The Tripotential Glial-Restricted Precursor (GRP) Cell and Glial Development in the Spinal Cord: Generation of Bipotential Oligodendrocyte-Type-2 Astrocyte Progenitor Cells and Dorsal–Ventral Differences in GRP Cell Function , 2002, The Journal of Neuroscience.

[62]  W. Schulz,et al.  Decrease of DNA methyltransferase 1 expression relative to cell proliferation in transitional cell carcinoma , 2003, International journal of cancer.

[63]  D. Louis,et al.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.

[64]  Webster K. Cavenee,et al.  Aberrant methylation of genes in low-grade astrocytomas , 2006, Brain Tumor Pathology.

[65]  M. Berger,et al.  Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. , 1996, Cancer research.

[66]  R. Ransohoff,et al.  The Chemokine Growth-Regulated Oncogene-α Promotes Spinal Cord Oligodendrocyte Precursor Proliferation , 1998, The Journal of Neuroscience.

[67]  J. Platt,et al.  Melanoma × macrophage hybrids with enhanced metastatic potential , 1998, Clinical & Experimental Metastasis.

[68]  S. Coons,et al.  Cytogenetic and flow cytometry DNA analysis of regional heterogeneity in a low grade human glioma. , 1995, Cancer research.

[69]  O. Bogler,et al.  A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. , 1996, Cancer research.

[70]  D. Gutmann,et al.  Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. , 2001, Cancer research.

[71]  S. Barnett,et al.  Oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells transformed with c-myc and H-ras form high-grade glioma after stereotactic injection into the rat brain. , 1998, Carcinogenesis.

[72]  G. Fuller,et al.  Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. , 2002, Cancer research.

[73]  David J. Anderson,et al.  The bHLH Transcription Factors OLIG2 and OLIG1 Couple Neuronal and Glial Subtype Specification , 2002, Cell.

[74]  K. Bhakoo,et al.  From rodent glial precursor cell to human glial neoplasia in the oligodendrocyte‐type‐2‐astrocyte lineage , 1995, Glia.

[75]  R A Betensky,et al.  Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.